A multicenter prospective single-arm study of robot-assisted partial nephrectomy for completely endophytic renal tumors

A multicenter prospective single-arm study of robot-assisted partial nephrectomy for completely endophytic renal tumors comparing with a historical control treated with traditional laparoscopic partial nephrectomy. - RAPNCET

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1052200016

Enrollment

100

Registered

2020-05-22

Start date

2020-07-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

completely endophytic renal tumors

Interventions

Laparoscopic partial nephrectomy using da vinci surgical system (DVSS)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) The tumor is diagnosed as the mass located i n the Tumors without tumor protrusion outward fr om renal cortex, either CT* abdomen scan or MRI (if the patient is unable to take the contrast agent) and an indication for partial nephrectomy. * slice of contrast enhanced CT abdomen must b e less than 5mm (2) The tumor is less than 7cm (cT1) (3) Detecting no metastasis of lymph node or intr a-abdominal organ by either contrast enhanced CT abdomen scan or MRI (if the patient is unable t o take the contrast agent). (cN0,cM0) (4) Detecting no metastasis by the contrast enhan ced CT chest scan or bone scintigraphy. (cM0) (5) Single tumor (6) More than 20 years of age at the informed con sent. (7) Written consent from the individual regarding research participation.

Exclusion criteria

Exclusion criteria: (1)Active Multiple cancer (2)History of kidney transplantation(recipient) (3)Receiving renal cancer treatment within 6 months from the date of consent for this clinical study. (4)High risk to general anesthesia (5)Dialysis patient (6)Pregnant, suspected of being pregnant, or lactating women. (7)Judged as an inappropriate patient by the investigator or sub-investigator at the hospital (site) for any other reasons.

Design outcomes

Primary

Measure	Time frame
warm ischemia time and tumor tissue negative	—

Secondary

Measure	Time frame
1) eGFR (Estimated Glomerular Filtration Rate) 2)Whether all of Trifecta (hereinafter a. To c. ) are satisfied. a.Tumor tissue negative at the resected margin. b.180-day eGFR is 90% or more of that before surgery. c.By 180 days, no pseudoaneurysms with Clavien-Dind o grade 3 or higher, no postoperative ble eding, or urinary fistula. 3)Raito of eGFR multiplied split (%) between pre- and post-operation by renal scintigraphy in operated kidney. 4)Achieved both tumor tissue negative and warm ischemia time within 25 min. 5)Overall survival 6)Relapse-free survival time 7)Deteriorated CKD free time	—

Measure

Time frame

1) eGFR (Estimated Glomerular Filtration Rate) 2)Whether all of Trifecta (hereinafter a. To c. ) are satisfied. a.Tumor tissue negative at the resected margin. b.180-day eGFR is 90% or more of that before surgery. c.By 180 days, no pseudoaneurysms with Clavien-Dind o grade 3 or higher, no postoperative ble eding, or urinary fistula. 3)Raito of eGFR multiplied split (%) between pre- and post-operation by renal scintigraphy in operated kidney. 4)Achieved both tumor tissue negative and warm ischemia time within 25 min. 5)Overall survival 6)Relapse-free survival time 7)Deteriorated CKD free time

—

Contacts

Public ContactNobuyuki Hinata

Hiroshima University Hospital

rapncet@med.kobe-u.ac.jp+81-82-257-5242

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026